PAMAM-drug complex for delivering anticancer drug across blood-brain barrier in-vitro and in-vivo

African Journal of Pharmacy and Pharmacology

Volumn 3, Issue 5, 2009, Pages 227-233

  Cui, Daming ^a   Xu, Qiwu ^a   Gu, Shixin ^a   Shi, Jinlong ^a   Che, Xiaoming ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Blood brain barrier; Doxorubicin; P glycoprotein; PAMAM

Indexed keywords

DENDRIMER; DOXORUBICIN; GLYCOPROTEIN P; POLYAMIDOAMINE; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; DRUG UPTAKE; ENDOTHELIUM CELL; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN;

EID: 77953663542     PISSN: None     EISSN: 19960816     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Abu Ajaj K, Kratz F (2009). Development of dual-acting prodrugs for circumventing multidrug resistance. Bio. Org. Med. Chem. Lett. 19(3):995-1000.
2. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003). Pglycoprotein: from genomics to mechanism. Oncogene. 22: 7468-7485.
3. Barancík M, Bohácová V, Sedlák J, Sulová Z, Breier A (2006). LY294, 002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci. 29(5):426-434
4. Caminade AM, Laurent R, Majoral JP (2005). Characterization of dendrimers. Adv. Drug Deliv. Rev. 57: 2130-2146.
5. Cheng Y, Xu T, Fu R (2005). Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. Eur. J. Med. Chem. 40: 1390-1393.
6. Chen JH, Wang L, Ling R, Yu L, Zhe W, Qing Y, Zhong M (2004). Body distribution of nanoparticle-containing adriamycin injected into the hepatic artery of hepatoma-bearing rats. Dig. Dis. Sci. 49: 1170-1173.
7. Chen Y, Dalwadi G, Benson HA (2004). Drug delivery across the blood-brain barrier. Curr. Drug. Deliv. 1: 361-376.
8. Constantinides PP, Wasan KM (2007). Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J. Pharm. Sci. 96(2):235-248
9. Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F (2005). Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J. Cont. Rel. 108: 84-96.
10. DeMatti CR, Huang B, Tomalia DA (2004). Designed dendrimer synthesis by self-assembly of single-site, ssDNA functionalized dendrons. Nano Lett 4: 771-777. (Pubitemid 38716325)
11. Dong J, Yu X, Wang L, Sun YB, Chen XJ, Wang GJ (2008). Effects of cyclosporin A and itraconazole on the pharmacokinetics of atorvastatin in rats. Acta Pharmacol Sin. 29(10): 1247-1252
12. Dufès C, Uchegbu I, Schätzlein AG (2005). Dendrimers in gene delivery. Adv. Drug Deliv Rev. 57: 2177-2202.
13. El-Sayed M, Rhodes CA, Ginski M, Ghandehari H (2003). Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers Int. J. Pharm. 265: 151-157. (Pubitemid 37176956)
14. Fant K, Esbjörner EK, Lincoln P, Nordén B (2008). DNA condensation by PAMAM dendrimers: self-assembly characteristics and effect on transcription. Biochemistry 47(6): 1732-1740
15. Ferreira AL, Matsubara LS, Matsubara BB (2008). Anthracycline-induced cardiotoxicity. Cardiovas. Hematol. Agents. Med. Chem. 6(4):278-281
16. Huang RQ, Ke WL, Liu Y, Jiang C, Pei YY (2008). The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials 29(2): 238-246 (Pubitemid 350016299)
17. Huang RQ, Qu YH, Ke WL, Zhu JH, Pei YY, Jiang C (2007). Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J. 21: 1117-1125. (Pubitemid 46495701)
18. Huber JD, Egleton RD, Davis TP (2001). Molecular physiology and pathophysiology od tight junctions in the blood-brain barrier. Trends Neurosci. 24: 719-725. (Pubitemid 33097539)
19. Jain KK (2007). Nanobiotechnology-based drug delivery to the central nervous system. Neurodegener Dis. 4(4): 287-291. (Pubitemid 47026182)
20. Jevprasesphant R, Penny J, Jalal R, Attwood D, McKeown NB, D'Emanuele A (2003). The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 252: 263-266.
21. Jevprasesphant R, Penny J, Attwood D, D'Emanuele A. (2004). Transport of dendrimer nanocarriers through epithelial cells via the transcellular route. J. Cont. Release. 97: 259-267.
22. Ke WL, Zhao YS, Huang RQ, Jiang C, Pei YY (2008). Enhanced oral bioavailability of doxorubicin in a dendrimer drug delivery system. J Pharm. Sci. 97(6): 2208-2216
23. Kitchens KM, El-Sayed ME, Ghandehari H (2005). Transepithelial and endothelial transport of poly (amidoamine) dendrimers. Adv. Drug Deliv. Rev. 57: 2163-2176.
24. Kondo A, Inoue T, Nagara H, Tateishi J, Fukui M (1987). Neurotoxicity of adriamycin passed through the transiently disrupted blood-brain barrier by mannitol in the rat brain. Brain Res. 412: 73-83. (Pubitemid 17096685)
25. Kuo YC, Kuo CY (2008). Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int. J. Pharm. 351(1-2): 271-281
26. La Vecchia C, Bosetti C (2003). Calcium channel blockers, verapamil and cancer risk. Eur. J. Cancer 39: 7-8. (Pubitemid 36005419)
27. Lesniak MS, Upadhyay U, Goodwin R, Tyler B, Brem H (2005). Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res. 25: 3825-3831. (Pubitemid 41665151)
28. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W, Duncan R (2000). Dendrimers: relation ship between structure and biocompatibility in vitro and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo J. Cont. Release 65:133-148. (Pubitemid 30122922)
29. Nam HY, Nam K, Hahn HJ, Kim BH, Lim HJ, Kim HJ, Choi JS, Park JS (2009). Biodegradable PAM-AM ester for enhanced transfection efficiency with low cytotoxicity, Biomaterials 30(4): 665-673
30. Papagiannaros A, Dimas K, Papaioannou GT, Demetzos C (2005). Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. Int. J. Pharm. 302:29-38.
31. Pardridge WM (2003). Blood-brain barrier drug tar-geting: the future of brain drug development. Mol. Interv. 3:90-105.
32. Schally AV (2008). New approaches to the therapy of various tumors based on peptide analogues. Horm. Metab. Res. 40(5): 315-322
33. Sharma A, Rao M, Miller R, Desai A (2005). Fluorometric assay for detection and quantitation of polyamidoamine dendrimers. Anal. Biochem. 344(1): 70-75.
34. Tilloy S, Monnaert V, Fenart L, Bricout H, Cecchelli R, Monflier E (2006). Methylated beta-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier: Bioorg. Med. Chem. Lett. 16: 2154-2157.
35. Wolburg H, Lippoldt A (2002). Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul. Pharmacol. 38:323-337.
36. Yang H, Morris JJ, Lopina ST (2004). Polyethylene glycolpolyamidoamine dendritic micelle as solubil-ity enhancer and the effect of the length of polyethylene glycol arms on the solubility of pyrene in water. J. Colloid Interface Sci. 273: 148-154. (Pubitemid 38407379)
37. Zhang L, Liu XD, Xie L, Wang GJ (2003). P-glyco-protein restricted transport of nimodipine across blood-brain barrier. Acta. Pharmacol. Sin. 24: 903-906.